Publications by authors named "Andrea Caprodossi"
Background: HER2 positive disease accounts for 15-20% of early breast cancer. Achieving a pathological complete response after neoadjuvant chemotherapy (NACT) improves prognosis and decreases risk of recurrence.
Case Report: Our case report aimed to highlight an emblematic clinical success and benefit of NACT with the addition of pertuzumab to the standard trastuzumab/taxane/anthracycline combination in a patient with a 9 cm breast neoplasm and extensive lymph node involvement (>4 pathological lymph nodes).
Article Synopsis
- Early access to medicines in Italy is complicated by uncertainty in evidence, making managed entry agreements (MEA) important in early access programs (EAP).
- A Focus Group of experts suggested that the current EAP should be reformed, highlighting issues like the prevalence of older products and significant administrative burdens in reimbursement.
- The group proposed new legislation for better regulation of EAP that includes specific medicine selections, real-world data collection, and integration of MEA into pricing and reimbursement discussions.